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BACKGROUND. Spindle and/or epithelioid melanocytic proliferations that display
overlapping histopathologic features of Spitz nevus and Spitz-like melanoma are
diagnostically difficult and controversial melanocytic tumors. There are reports of
such lesions metastasizing to regional lymph nodes, with a few widely disseminat-
ing, resulting in death.
METHODS. The authors reviewed clinical and histopathologic data on all patients
with atypical or borderline spitzoid melanocytic proliferations who underwent
sentinel lymph node biopsy (SLNB). They examined how frequently histologically
problematic or borderline spitzoid melanocytic lesions metastasized to sentinel
lymph nodes (SLNs) and which clinical or histologic features, if any, predisposed
patients to a higher risk lesion.
RESULTS. Six male patients and 12 female patients, ages 5–32 years (mean, 16
years), had tumors ranging in size from 1.2 mm to 7.9 mm (mean, 3.5 mm) in
thickness. Atypical histologic features that were present most frequently included
incomplete maturation (18 of 18 patients), deep dermal mitoses (16 of 18 patients),
nuclear pleomorphism (10 of 18 patients), and focal sheet-like growth (10 of 18
patients). Eight of 18 patients (44%) had SLN metastasis and were offered adjuvant
treatment. One of eight patients with SLN positive results who underwent regional
lymphadenectomy had one additional involved lymph node. All 18 patients were
alive and well with no evidence of recurrent or metastatic disease after a follow-up
of 3– 42 months (mean, 12 months).
CONCLUSIONS. Histologically atypical or borderline spitzoid, melanocytic tumors
are diagnostically challenging and controversial melanocytic lesions, some of
which represent unrecognized melanomas. SLNB aids in confirming a diagnosis of
melanoma and identifies patients who may benefit from early therapeutic lymph
node dissection and/or adjuvant therapy. Cancer 2003;97:499 –507.
© 2003 American Cancer Society.
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In a landmark study on melanomas in childhood,1 Sophie Spitzobserved that only 1 of 13 patients with juvenile melanoma had a
malignant and fatal course. In her analysis, she concluded that the
presence of giant cells in nearly half of the benign tumors, now
eponymously called Spitz nevus, was a histologic finding that helped
to distinguish them from melanoma. Since then, many have studied
the histology of spindle and epithelioid melanocytic proliferations to
uncover features that may help to differentiate benign Spitz nevus
from melanoma with Spitz-like features. Although significant
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progress has been made in defining histologic criteria
for Spitz nevus and Spitz-like melanoma, the diagno-
sis of atypical spindle and epithelioid melanocytic
proliferations remains a contentious area in dermato-
pathology with repercussions that extend to patient
management.2
Although most spindle and epithelioid melano-
cytic proliferations readily are classifiable histologi-
cally as Spitz nevus or melanoma with Spitz-like fea-
tures,1,3–5 there is a subset of problematic and
diagnostically challenging melanocytic lesions vari-
ably designated as atypical Spitz tumor, atypical Spitz
nevus, Spitz-like lesion in the borderline category of
indeterminate malignant potential, and diagnostically
controversial spitzoid melanocytic tumors, that defy
classification into either category even by the most
experienced dermatopathologists.2,6 –10 These lesions
simultaneously exhibit some histomorphologic fea-
tures of classic Spitz nevus and Spitz-like melanoma,
making diagnostic assignment to either Spitz nevus or
Spitz-like melanoma difficult, controversial, and
sometimes erroneous.
The biologic behavior of these problematic atyp-
ical spitzoid melanocytic lesions has not been eluci-
dated clearly. Experts often regard these lesions as
having an indeterminate malignant potential, yet
there is excellent documentation of histologically
atypical or controversial, spitzoid, melanocytic lesions
metastasizing to regional lymph nodes,8,11–13 some
with wide dissemination and fatal outcome.2,7,14,15 It is
reasonable to conclude, in retrospect, that these le-
sions are classified better as melanomas.
For these reasons, at our institution, we proceed
cautiously and conservatively when faced with mela-
nocytic lesions classified as atypical Spitz tumor, bor-
derline epithelioid melanocytic proliferation, or atyp-
ical epithelioid melanocytic proliferation of unknown
biologic potential for which a consensus in diagnosis
among experts cannot be reached. We recommend
intraoperative lymphatic mapping (IOLM) and senti-
nel lymph node biopsy (SLNB) to patients with tumors
that exceed 1 mm in Breslow depth or  1 mm in
Breslow depth with adverse histologic features, such
as ulceration. Defining the sentinel lymph node (SLN)
status provides valuable information that better de-
fines the biologic potential of these diagnostically
challenging lesions.8,16 This report on our institutional
experience with SLNB for patients with problematic
atypical spitzoid melanocytic lesions is the largest se-
ries to date.
MATERIALS AND METHODS
After obtaining approval from the University of Mich-
igan Institutional Review Board, we queried the mel-
anoma and pathology data bases at the University of
Michigan Medical Center for patients with atypical
spitzoid melanocytic proliferations that fell within any
of several designations (including atypical Spitz tu-
mor, markedly atypical Spitz nevus, atypical epithe-
lioid melanocytic proliferation of uncertain biologic
potential, or borderline epithelioid melanocytic neo-
plasm) who underwent IOLM and SLNB. Also in-
cluded were patients who were diagnosed with mela-
noma with spitzoid features for whom there was a
discordance in diagnosis among expert dermato-
pathologists and patients in whom the diagnosis of
melanoma could not be excluded. Clinical data and
histopathologic material from primary lesions, SLNs,
and regional lymphadenectomy specimens (when ap-
plicable) were retrospectively reviewed.
The clinical data extracted included patient age,
gender, location of the primary lesion, number of
SLNs obtained, and site of lymphadenectomy, if ap-
plicable. Histologic parameters of the primary lesion
that were assessed included the presence or absence
of Kamino bodies; tumor thickness measured in mil-
limeters (Breslow depth); Clark level; presence or ab-
sence of ulceration; mitotic rate (including deep
and/or atypical mitoses); and atypical or disturbing
growth pattern, such as incomplete maturation/zona-
tion or focal, confluent, or sheet-like growth. At least
one and frequently all three board-certified demato-
pathologists (L.D.S., D.R.F., and L.L.) evaluated the
histopathologic material. Because of the borderline
nature of many of the primary lesions, a consensus in
diagnosis frequently could not be achieved. The dif-
fering opinions were recorded.
The procedure for IOLM and SLNB used in our
institution is similar to that previously described.17–19
A combination of immediate preoperative lympho-
scintigraphy with unfiltered 99mTC-sulfur colloid and
intraoperative lymphatic mapping using both a  de-
tector and vital blue dye (Lymphazurin 1%; Hirsch
Industries, Richmond, VA) was used to identify the
SLN in all patients. The protocol for evaluating SLNs at
our institution was as follows: SLNs were sectioned
serially at a thickness of 2–3 mm, fixed in formalin,
and embedded in paraffin. Two serial, 5-m sections
from each SLN tissue block were stained with hema-
toxylin and eosin (H&E) for routine histologic exami-
nation. For blocks in which obvious metastatic tumor
was not identified in routine sections, immunohisto-
chemical stains were performed on every SLN tissue
block. One serial section from each SLN block was
immunostained for S100 protein (1:1000 dilution;
Dako, Carpinteria, CA), Melan-A (1:12:5 dilution;
Dako), and HMB-45 (1:100 dilution; Dako). In blocks
in which only small foci suspicious for tumor were
500 CANCER January 15, 2003 / Volume 97 / Number 2
present in H&E-stained sections, all three immunos-
tains were obtained to confirm the impression of met-
astatic involvement.
RESULTS
The clinical findings are summarized in Table 1. We
identified 18 patients from January 1998 to December
2001. Twelve patients were female, and 6 patients
were male. Their ages at the time of diagnosis ranged
from 5 years to 32 years (mean age, 16 years). The
majority of lesions were found on the extremities (9 of
18 lesions), whereas 6 lesions were located on the
trunk, and 3 lesions were located in the head and neck
region.
Pertinent histopathologic features also are in-
cluded in Table 1. All tumors were spindle and/or
epithelioid melanocytic proliferations and displayed
at least two other features commonly seen in conven-
tional Spitz nevus: epidermal hyperplasia, symmetri-
cal growth, circumscribed margins, papillary dermal
edema, or Kamino bodies. The most prominent atyp-
ical histologic features were as follows. In all tumors
(18 of 18 tumors), there was incomplete or no matu-
ration/zonation of dermal melanocytes, identified as a
failure of dermal melanocytes to completely disperse
as single cells that insinuate themselves between col-
lagen bundles and a failure to diminish in size with
dermal descent. In 16 of 18 tumors, mitotic activity
was noted in the lower one-third of the tumor, ranging
from 1 mitoses per mm2 to 5 mitoses per mm2. There
were no atypical division figures. We noted variability
in nuclear size and shape (nuclear pleomorphism) in
10 of 18 tumors. An aberrant dermal growth pattern
that was characterized by focal sheet-like growth was
present in 10 of 18 tumors. None of the tumors were
ulcerated. In addition, no tumor demonstrated up-
ward, pagetoid scattering of melanocytes. Variable
numbers of eosinophilic Kamino bodies were identi-
fied in three lymph node positive primary tumors and
in five lymph node negative primary tumors.
At the time of presentation, a histologic diagnosis
of atypical epithelioid melanocytic proliferation of un-
certain biologic potential or atypical Spitz tumor of
uncertain biologic potential was rendered in 10 of 18
patients. Figures 1 and 2 illustrate the histologic fea-
tures of one such patient (Patient 8). Figure 3 demon-
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1 10 F R eyebrow AS 3.3/V — 3 X X No R preauric 1 of 3 No 0 of 47 AW (5)
2 17 F Sacrum SN(2),AS,SM 1.3/IV X 2 X — Few L groin 1 of 2 No 0 of 14 AW (2)
3 24 F L shoulder AS,SM(3) 1.5/IV X 4 X — No L axilla 2 of 5 No 0 of 11 AW (17)
4 8 M R ear AS(3) 3.6/V X 1 X X Few R neck 1 of 2 Yes 0 of 44 AW (7)
5 12 M R ankle AS(3) 4.0/IV — 1 X X No R groin 2 of 11 No 1 of 13 AW (7)
6 5 F L calf AS(2) 3.0/IV X 2 X — No L groin 2 of 2 No 0 of 14 AW (8)
7 29 F Back AS 2.2/IV X — X — No R axilla 1 of 3 Yes 0 of 13 AW (8)
8 8 M R thigh AS(3) 3.5/IV X 4 X X Many R groin 1 of 2 No 0 of 10 AW (14)
9 32 M R thigh AS(2) 4.5/IV — 1 X — No R groin 0 of 2 No — AW (36)
10 24 F R leg AS, SM 1.2/IV — 1 X — Many R groin 0 of 1 No — AW (11)
11 22 M Back AS(3) 3.6/IV X 1 X X No R axilla 0 of 4 No — AW (10)
12 21 M L arm AS,SM(2) 2.5/IV X 1 X X No L axilla 0 of 1 Yes — AW (7)
13 16 F L buttock AS,SM(2) 6.5/IV — 5 X — Few L groin 0 of 4 No — AW (7)
14 16 F L thigh AS,SM 1.3/IV X — X — No L groin 0 of 1 No — AW (7)
15 13 F L ear AS(2) 7.0/IV — 2 X X No L neck 0 of 1 No — AW (19)
16 31 F L arm AS(2) 2.5/IV — 2 X X Many L axilla 0 of 3 No — AW (3)
17 12 F R arm AS,SM(2) 2.9/IV X 1 X X Many R axilla 0 of 3 Yes — AW (5)
18 11 F L flank AS,SM(2) 7.9/IV — 4 X X Few L axilla 0 of 2 No — AW (4)
NP: nuclear pleomorphism; DM: dermal mitoses; NM: incomplete or no maturation/zonation of dermal melanocytes; FCG: focal confluent (sheet-like) growth in dermis; SN: Spitz nevus; F: female; M: male; R: right;
L: left; AS: atypical Spitz tumor/atypical epithelioid melanocytic proliferation of uncertain biologic potential; SM: Spitz-like melanoma; AW: alive and well with no evidence of disease.
a Atypical histologic features (marked with X) were noted in tumors.
b Histologic diagnoses at biopsy by staff and consultants: numbers in parentheses indicate the number of consultants who reached the same diagnoses (if greater than one).
c If deep (DM) were present, then the numbers of mitoses per mm2 in the lower one-third of the tumor are indicated.
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strates the SLN metastasis identified in this patient. In
8 of 10 patients, the lesions were reviewed by at least
1 other dermatopathologist who concurred with the
diagnosis. The remaining eight patients had slightly
more varied diagnoses, and concordance could not be
reached among the dermatopathologists at our insti-
tution. These lesions were interpreted as melanoma
with Spitzoid features by at least one dermatopatholo-
gist; however, atypical, epithelioid, melanocytic pro-
liferation/atypical Spitz tumor of uncertain biologic
potential was favored by at least one other dermato-
pathologist. There was only one patient for whom a
diagnosis of benign Spitz nevus was proposed (Patient
2). This lesion was classified as Spitz nevus by two
highly experienced melanoma consultants outside of
our institution. At our institution, one dermato-
pathologist favored melanoma, and another favored
atypical Spitz tumor. Figures 4 and 5 demonstrate the
Spitz-like and atypical features of this lesion. SLN me-
tastasis was identified subsequently in this patient
(Fig. 6).
SLN metastasis was identified in 8 of 18 patients
(44%). In all eight patients with positive lymph nodes,
tumor cells were found in the subcapsular sinuses and
lymph node parenchyma. None of the 8 patients with
positive lymph nodes had large metastases that par-
tially or totally replaced the lymph node. Metastatic
foci varied in size from 0.1 mm to 1.0 mm (Table 2).
Immunostaining was required in all eight tumors, be-
cause the metastatic foci either were not detected in
the H&E-stained sections (in 2 of 8 patients) or were
few or small in size, requiring immunophenotypic dis-
tinction from sinus histiocytes or macrophage aggre-
gates. Nonspitzoid, capsular nevi were found in 2 of 8
patients with positive lymph nodes and in 2 of 10
patients with negative lymph nodes (Table 1).
The mean age of patients with positive lymph
nodes was 14 years (range, 5–29 years). The mean age
of patients with negative lymph nodes was 23 years
(range, 11–32 years). The mean Breslow depth for pa-
tients with positive lymph nodes was 2.85 mm (range,
1.3– 4.0 mm). The mean Breslow depth for patients
FIGURE 1. On scanning magnification, an atypical Spitz tumor from Patient
8 has slight epidermal hyperplasia and a circumscribed, wedge-shaped, and
symmetrical silhouette.
FIGURE 2. In a section of deep dermis from Patient 8, at high magnification,
spindle and epithelioid melanocytes do not mature with descent into the dermis
and display focal sheet-like growth, moderate nuclear pleomorphism, and
division figures (arrowhead).
FIGURE 3. HMB-45-immunostained sections from Patient 8 show tumor cells
lodged in the subcapsular sinus with a few scattered singly in the parenchyma
(inset).
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with negative lymph nodes was 3.99 mm (range, 1.2–
7.9 mm). The age, gender, site of the primary tumor,
histologic diagnosis, and atypical histologic features
observed did not appear to predict or predispose pa-
tients to lymph node metastasis. The histologic diag-
nosis rendered in six of eight patients with positive
lymph nodes was atypical Spitz tumor/atypical epi-
thelioid melanocytic proliferation of uncertain bio-
logic potential. In the other two patients, a consensus
in diagnosis could not be reached, and melanoma was
favored by at least one dermatopathologist. In five of
eight patients with positive lymph nodes, one SLN
contained tumor, whereas in three of eight patients
with positive lymph nodes, two SLNs were involved.
All patients with a positive SLN underwent therapeutic
lymph node dissection (TLND). One additional non-
SLN in one patient (13%) (Patient 5) was positive for
metastatic melanoma.
All eight patients with positive lymph nodes were
FIGURE 4. A controversial Spitz tumor (approximately 4 mm in greatest
dimension) on scanning magnification from Patient 2 shows some histologic
features of a classic Spitz nevus, including epidermal hyperplasia; a circum-
scribed, symmetrical, and somewhat wedge-shaped silhouette; and papillary
dermal edema. An atypical finding (arrowheads) is the presence of nested
melanocytes in the deep dermis intermingled with more dispersed melanocytes
(incomplete maturation/zonation).
FIGURE 5. The controversial Spitz tumor from Patient 2 at high magnification
displayed division figures in deep dermis (asterisk), nuclear pleomorphism
(upward arrowhead), and large nests intermingled with more dispersed mela-
nocytes (leftward arrowheads), indicating incomplete maturation/zonation.
FIGURE 6. Atypical epithelioid melanocytes from Patient 2 are found in the
substance of a sentinel lymph node in hematoxylin and eosin-stained sections
(arrowheads) and in Melan-A and S100-immunostained sections (inset).
TABLE 2








sectionsa S100b Melan-Ab HMB-45b
1 0.1–0.2    NR
2 0.5–0.9    
3 0.3–1.0    
4 0.1–0.2 —   —
5 0.1–0.8    —
6 0.3–1.0    
7 0.1–0.2 — NR  —
8 0.1–0.8    
H&E: hematoxylin and eosin; NR: tumor not represented (indeterminate for immunostaining).
a : Tumor detected in H&E sections;—: tumor not detected in H&E sections.
b : Tumor positive for immunostaining;—: tumor negative for immunostaining.
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offered adjuvant treatment. Two patients received in-
vestigational melanoma vaccines at other institutions,
and six patients received interferon-2b. All patients
were without evidence of recurrent disease, in remis-
sion, at 3– 42 months of follow-up (mean, 12 months).
DISCUSSION
The concept that spindle and epithelioid, melanocytic
proliferations display morphologic features in a histo-
logic continuum, with benign Spitz nevus at one end
and Spitz-like melanoma at the other, has been ac-
cepted by many investigators.6,7,20 The reports of
widely metastasizing disease from lesions not histo-
logically discernable from banal Spitz nevi21–23 sup-
port this concept of a phenotypic continuum and un-
derscore the point that the accurate diagnosis of
melanoma with Spitzoid features can be problematic,
even for the most experienced dermatopathologist.
The stereotypic benign Spitz nevus20,24,25 is
domed shaped, symmetrical in silhouette, laterally
well marginated, and consists of large spindle and
epithelioid melanocytes uniformly arrayed as nests
along the junction of hyperplastic epidermis. Artifac-
tual clefts may form around junctional nests. Eosino-
philic Kamino bodies commonly are deposited along
the dermoepidermal interface. Dermal melanocytes
mature with descent into the dermis and lack signifi-
cant pleomorphism and deep mitotic activity. A mela-
nocytic lesion with this appearance is recognized
readily as a benign Spitz nevus, as are other tumors
that deviate only slightly from this stylized depiction.
At the other end of the histologic continuum are
spindle and epithelioid melanocytic proliferations that
retain some histologic attributes of Spitz nevus, but
the preponderance of features are those of conven-
tional melanoma. Piepkorn cites as worrisome find-
ings high-grade nuclear atypia, high mitotic rate with
deep dermal mitoses or atypical mitoses, no or only
focal maturation at the base, deep penetration into
lower dermis or subcutis, ulceration, and large le-
sional size.20 Other authors have cited similar criteria,
as well as other criteria, for the diagnosis of Spitz-like
melanoma, such as marked pagetoid spread,26 single-
cell epidermal invasion below parakeratosis,27 asym-
metry,5 destruction of collagen,3 substantial and/or
deep melanization,21 and variability of cellular fea-
tures between adjacent cell groups.4 Reed proposed
that confluent or expansile, nodular aggregates of
atypical Spitz-like cells in the dermis represent a ver-
tical growth phase or possess a competence for me-
tastasis and are regarded best as minimal deviation
melanoma, Spitz-like type.9 Dermatopathologists gen-
erally agree that no single histologic finding is diag-
nostic in and of itself for Spitz nevus or Spitz-like
melanoma. Rather, the diagnosis depends on the as-
sessment of multiple histomorphologic features and
often requires clinical correlation.3,28 –30 If a spindle
and epithelioid melanocytic tumor demonstrates
many or most of the above-cited atypical or worri-
some histologic features, then it is recognizable as
Spitz-like melanoma.
Spindle and epithelioid melanocytic proliferations
that fall in the central portion of the histologic con-
tinuum, variously termed atypical Spitz nevus, atypical
Spitz tumor,6,7,20 diagnostically controversial Spitzoid
melanocytic tumors,8 and Spitz-like lesion in the bor-
derline category of indeterminate malignant potential,9
defy classification as Spitz nevus or Spitz-like melano-
ma.2,6 –9 These melanocytic lesions deviate substan-
tially from the stylized depiction of Spitz nevus, re-
taining some attributes of classic Spitz nevus but also
exhibiting a few or several findings for melanoma. All
18 patients in this study had spindle and/or epithe-
lioid melanocytes and at least 2 other features of clas-
sic Spitz nevus. The most notable atypical histologic
features were incomplete maturation, deep dermal
mitoses, nuclear pleomorphism, and focal sheet-like
growth.
Histologic criteria for the diagnosis of atypical
Spitz tumors have been proposed,7,30 but the tumors
nevertheless cause diagnostic controversy when they
are evaluated by dermatopathologists because of in-
terobserver variation in the interpretation and in the
application of criteria.2 The obvious concern is the
accurate diagnosis of lesions that are melanoma. At a
minimum, lesions that are potentially higher risk, bor-
derline, or of indeterminate biologic potential need to
be identified. In the current study, we were able to
achieve some consensus in recognizing an atypical
Spitz tumor/atypical, epithelioid, melanocytic prolif-
eration of uncertain biologic potential. This diagnosis
was rendered in 10 of 18 patients. In the other eight
patients, one or more dermatopathologist favored a
diagnosis of melanoma. The most striking example of
discordance in diagnosis was for Patient 2 (Fig. 4), for
whom the diagnoses ranged from wholly benign to
malignant, all of which were rendered by highly expe-
rienced dermatopathologists with expertise in pig-
mented lesions.
In light of the controversy surrounding the histo-
logic diagnosis of problematic atypical spitzoid mela-
nocytic lesions and, as discussed above, the likelihood
that some represent melanomas, ancillary diagnostic
techniques that may be better at discriminating be-
nign lesions from malignant melanocytic lesions are
needed greatly. Immunohistochemical staining with
Ki-67,31–34 Ki-67 and bcl-2,35 and proliferating cell nu-
clear antigen36,37 has shown some promise in discrim-
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inating melanoma from benign nevi, including Spitz
nevi. In situ hybridization to detect expression of
melastatin,38 a melanocyte specific gene that is ex-
pressed in melanoma at levels inversely proportional
to metastatic rates, is useful in predicting metastasis
and disease free survival in adult patients with mela-
noma39 and may be useful in predicting which atypi-
cal spitzoid lesion may be malignant. DNA in situ
hybridization using a chromosome-1 centromere
probe on routinely processed paraffin sections report-
edly showed a clear difference in the number of aber-
rant (aneuploid) nuclei between Spitz nevi and mela-
noma.40 When it was applied to five problematic Spitz
tumors that initially were misdiagnosed as Spitz nevi
and that metastasized later, the technique retrospec-
tively identified three of five tumors as melanoma.40
Recently, Bastian et al., employing the technique of
comparative genomic hybridization, observed no
chromosomal aberrations in 13 of 17 Spitz nevi and
found gains in the p arm of chromosome 11 or chro-
mosome 7q21-qter in the remaining 4 Spitz nevi.41
Because melanoma reportedly shows frequent dele-
tions of chromosomes 9p, 10q, 6q, 8p and gains of
chromosomes 7, 8, 6p, and 1q, this technique may be
applied to diagnostically difficult and controversial
spitzoid lesions to determine which tumors have cy-
togenetic findings of melanoma or Spitz nevus.41 Al-
though these techniques are promising, they require
further testing. Currently, no single technique has
been found that unequivocally discriminates among
these borderline lesions; and, clearly, light microscopy
alone has its limitations.
We are in strong agreement with the proposal by
Kelley and Cockerell that, in select patients, SLNB is a
useful adjunct in the management of histologically
difficult melanocytic lesions that measure  1.0 mm
in thickness.16 The most powerful predictor of overall
survival for melanoma is the status of the regional
lymph nodes. IOLM and SLNB are procedures with
low morbidity and are highly accurate for staging the
entire regional lymph node basin, sparing patients
with negative SLNB results the morbidity of undergo-
ing TLND. In addition, patients with positive SLNB
results are candidates for early intervention with po-
tentially lifesaving TLND and adjuvant therapy, such
as interferon-2b. In keeping with criteria for the di-
agnosis of metastatic melanoma in SLNs,42 if atypical
melanocytic cells are identified in the parenchyma or
subcapsular sinuses of the SLN(s), then the atypical or
controversial, spitzoid, melanocytic lesion should be
reclassified as melanoma.8,13 Although a negative
SLNB result does not exclude melanoma, it offers
some reassurance to patients that their tumor may be
confined to the skin. In this way, results of SLNB may
identify high-risk patients who require closer surveil-
lance and who may benefit from additional therapy. In
the current study, 8 of 18 patients (44%) with atypical
spitzoid melanocytic lesions were reclassified as mel-
anoma based on positive SLNB results. These results
were comparable to those observed in another study
in which 5 of 10 (50%) diagnostically controversial
spitzoid tumors metastasized to SLNs.8
The presence of a positive SLN(s) supports a di-
agnosis of melanoma in these problematic spitzoid
melanocytic lesions. Because it is recognized that cer-
tain benign tumors, such as cellular blue nevi, may be
found in regional lymph node parenchyma and sub-
capsular sinuses,43– 45 some investigators have argued
that finding metastatic deposits of Spitz-like tumor in
an SLN is not sine que non evidence of metastatic
melanoma. It has been suggested that these deposits
in the parenchyma and subcapsular sinuses of the
lymph node may represent lymph node Spitz nevi and
not metastatic melanoma.46 Investigators have made
some strides in an attempt to clarify this contentious
issue. Cytogenetic analyses of limited numbers of
atypical or controversial Spitz tumors that metastasize
to lymph nodes have documented cytogenetic abnor-
malities more in keeping with melanoma and not seen
in Spitz nevus. Smith et al. performed cytogenetic
analysis on an atypical Spitz tumor from the right
cheek of a girl age 18 months that metastasized to an
ipsilateral lymph node in the submandibular area.12
Karyotypes of both the primary tumor and the meta-
static tumor deposit yielded an abnormal chromo-
some 6, with deletion of a portion of the normal long
arm of chromosome 6 and replacement by chromo-
somal material of unknown origin: findings most con-
sistent with melanoma.12 De Wit et al. performed DNA
in situ hybridization using a chromosome-1 centro-
mere probe on 15 Spitz nevi, 15 typical melanomas,
and 5 problematic Spitz tumors that were classified
initially as Spitz nevus and that later metastasized or
displayed a malignant phenotype on recurrence.40 In
three of five problematic Spitz tumors and in many of
the typical melanomas, those authors demonstrated
supernumerary aberrations of chromosome 1 sugges-
tive of aneuploidy, whereas Spitz nevi were euploid.40
When these findings are coupled with reports of atyp-
ical, controversial, or problematic Spitz tumors dis-
seminating with a lethal outcome,2,7,14,15,26,47– 49 it is
completely reasonable and tenable to regard an atyp-
ical Spitz tumor found in the lymph node parenchyma
as biologically malignant.
The high frequency of metastasis observed in our
study (44%) and in another study (50%)8 is disturbing
but not unexpected. For melanoma measuring 2– 4
mm in tumor thickness, occult metastatic disease
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ranges from approximately 40% to 50%.50 The rate of
positivity for SLNB increases as the tumor thickness
increases from  5% for melanoma measuring  1
mm thick to 30 –50% for tumors measuring  4.0 mm
thick. The tumors in this study had a mean Breslow
depth of 3.5 mm (range, 1.2–7.9 mm) with a metastatic
rate of 44%. These results are very compatible with
what is known about the behavior of melanoma. Be-
cause of our limited follow-up period (mean, 12
months), little can be said at this time regarding the
biologic significance of a positive SLN in this subset of
patients. We are in complete agreement with Lohm-
ann et al. that long-term follow-up of these patients is
necessary before we know where these lesions fall
within the spectrum of conventional melanoma.8
What should not be missed from this discussion is
acknowledgement of our patients’ ages (mean, 16
years) and a clear-cut understanding that SLN metas-
tases were identified in young children. The mean age
of patients with positive SLNs was 14 years, including
1 child age 5 years, 2 children age 8 years, 1 child age
10 years, and one child age 12 years. It has been a long
regarded axiom that melanoma in children is exceed-
ingly rare. Accordingly, dermatopathologists are cau-
tious in rendering a diagnosis of melanoma in chil-
dren and adolescents. It is of paramount importance
to recognize that atypical borderline melanocytic pro-
liferations do occur in this subset of patients and that
some of these lesions, in fact, are melanomas.
In summary, atypical spitzoid melanocytic prolif-
erations are diagnostically challenging and controver-
sial melanocytic lesions. For lesions that measure  1
mm in Breslow depth for which a consensus in diag-
nosis cannot be reached among expert dermato-
pathologists and in which it is felt that the biologic
potential of the lesion is uncertain and/or melanoma
cannot be excluded, SLNB should be considered as a
useful adjunct in patient management because of the
diagnostic and prognostic information it provides.
The utility of SLNB for patients with problematic spit-
zoid melanocytic lesions ultimately may have its
greatest clinical relevance when it comes to the man-
agement of younger patients. A younger age alone
should not dissuade physicians from evaluating SLNs
in the context of a problematic or diagnostically chal-
lenging spitzoid lesion, because some of these lesions,
in fact, are melanomas. It is unclear whether this class
of tumors is a homogenous population that behaves
like conventional melanoma or behaves differently.
Unraveling the biologic nature of atypical spitzoid
melanocytic lesions will require long-term surveil-
lance of patients and further study with new molecu-
lar diagnostic techniques. Until such results are avail-
able, atypical spitzoid melanocytic lesions that
metastasize to SLNs are best regarded as melanomas.
Results of SLNB can clarify the diagnosis and aid in
selectively directing therapy and management.
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